Get the Stockscreener App
1.52
0.65%
-0.01
Cyclerion Therapeutics Inc stock is traded at $1.52, with a volume of 100.04K.
It is down -0.65% in the last 24 hours and up +0.66% over the past month.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
See More
Previous Close:
$1.53
Open:
$1.53
24h Volume:
100.04K
Relative Volume:
0.06
Market Cap:
$5.79M
Revenue:
$556.00K
Net Income/Loss:
$-5.28M
P/E Ratio:
-0.7103
EPS:
-2.14
Net Cash Flow:
$-6.23M
1W Performance:
-15.56%
1M Performance:
+0.66%
6M Performance:
-53.94%
1Y Performance:
-47.95%
1-Day Range:
$1.48
$1.60
1-Week Range:
$1.48
$2.00
52-Week Range:
$1.16
$6.25
Cyclerion Therapeutics Inc Stock (CYCN) Company Profile
Name
Cyclerion Therapeutics Inc
Sector
Industry
Phone
617-621-7722
Address
301 BINNEY STREET, CAMBRIDGE, MA
Compare CYCN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYCN
Cyclerion Therapeutics Inc
|
1.52 | 5.82M | 556.00K | -5.28M | -6.23M | -2.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.75 | 115.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
756.00 | 79.76B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
802.61 | 50.16B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
365.43 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.58 | 38.85B | 4.98B | 69.59M | 525.67M | 0.5197 |
Cyclerion Therapeutics Inc Stock (CYCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-21 | Initiated | Truist | Buy |
| Sep-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-03-19 | Initiated | Credit Suisse | Neutral |
Cyclerion Therapeutics Inc Stock (CYCN) Latest News
Top Penny Stocks To Follow NowJanuary 6th - MarketBeat
Is Cyclerion Therapeutics Inc. stock a safe buy before earningsJuly 2025 Momentum & AI Based Buy and Sell Signals - Улправда
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
Why Cyclerion Therapeutics Inc. stock could rally in 2025Rate Hike & Real-Time Buy Zone Alerts - Улправда
Why retail investors favor Cyclerion Therapeutics Inc. stockTreasury Yields & Daily Entry Point Trade Alerts - Улправда
Top Penny Stocks To Follow Now – January 6th - Defense World
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Will Cyclerion Therapeutics Inc. stock benefit from upcoming earnings reports2026 world cup usa national team round of 32 playmakers high defensive line expert forecast expert opinion - ulpravda.ru
Cyclerion Therapeutics, Inc. (CYCN) Discusses Medsteer Development Collaboration and Updates on Phase 2 Proof-of-Concept Study in Treatment-Resistant DepressionSlideshow (NASDAQ:CYCN) 2026-01-07 - Seeking Alpha
Exciting Surge in Cyclerion: What’s Next? - StocksToTrade
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Cyclerion Therapeutics Collaboration Sparks Curiosity - timothysykes.com
Cyclerion, Medsteer form strategic anesthetic technology alliance - TipRanks
Cyclerion Therapeutics stock jumps in premarket after Medsteer deal — what CYCN investors watch next - TechStock²
Stay updated with the stocks that are on the move in today's pre-market session. - Chartmill
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression - Sahm
Morning Market Movers: CYCN, AZI, AEVA, OS See Big Swings - RTTNews
Cyclerion (CYCN) Enters Exclusive Collaboration with Medsteer to Advance CYC-126 Clinical Trials - Intellectia AI
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Cyclerion partners with Medsteer to advance depression treatment platform By Investing.com - Investing.com Nigeria
Cyclerion Expands Partnership With Medsteer; Plans Phase 2 Trial Of CYC-126 In 2H 2026; Stock Up - RTTNews
Why Cyclerion Therapeutics Shares Are Trading Higher By 44%; Here Are 20 Stocks Moving Premarket - Benzinga
Critical Review: Cyclerion Therapeutics (NASDAQ:CYCN) & BeyondSpring (NASDAQ:BYSI) - Defense World
Cyclerion Therapeutics Inc. (CYCN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Cyclerion announces strategic agreement with Medsteer - marketscreener.com
Cyclerion Therapeutics (CYCN) Enhances Depression Treatment Prog - GuruFocus
Wondering what's happening in today's after-hours session? - Chartmill
Cyclerion partners with Medsteer to advance depression treatment platform - Investing.com India
Cyclerion Therapeutics stock soars after strategic Medsteer collaboration By Investing.com - Investing.com Nigeria
Cyclerion Therapeutics stock soars after strategic Medsteer collaboration - Investing.com
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Cyclerion Therapeutics, Inc. Announces Progress Toward Initiating Phase 2 Proof-Of-Concept Study for CYC-126 in Treatment-Resistant Depression - marketscreener.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
ICICI Prudential AMC Ltd (542629) Quarterly Results Are OutMonthly Performance Summary & Superior Wealth Building - bollywoodhelpline.com
Cyclerion Therapeutics Inc Stock Analysis and ForecastDividend Stability Analysis & Turn Bull Runs into Life-Changing Wealth - earlytimes.in
Critical Contrast: Cyclerion Therapeutics (NASDAQ:CYCN) versus Response Genetics (OTCMKTS:RGDXQ) - Defense World
Panjon Limited Flashes Buy Signal on Multi Timeframe ChartMoving Average Crossovers & High Return Wealth Building - bollywoodhelpline.com
Cyclerion Therapeutics Relaunches with Neuropsychiatric Focus - MSN
Will Cyclerion Therapeutics Inc. stock reach all time highs in 2025Weekly Trend Summary & Reliable Entry Point Alerts - Улправда
Should I hold or sell Cyclerion Therapeutics Inc. stock in 20252025 Geopolitical Influence & Technical Pattern Recognition Alerts - Улправда
How Cyclerion Therapeutics Inc. stock benefits from strong dollarJuly 2025 Institutional & Daily Risk Controlled Trade Plans - Улправда
Rate Hike: Will Cyclerion Therapeutics Inc. stock benefit from upcoming earnings reports2025 Fundamental Recap & Stock Portfolio Risk Management - Улправда
Cyclerion Therapeutics (NASDAQ:CYCN) Shares Down 0.7% – Should You Sell? - Defense World
Cyclerion Therapeutics Earnings Notes - Trefis
Can Cyclerion Therapeutics Inc. stock sustain institutional interestTrade Performance Summary & Safe Swing Trade Setups - Newser
Does Cyclerion Therapeutics Inc. stock trade at a discount to peersWeekly Loss Report & Verified Momentum Watchlists - Newser
How currency fluctuations impact Cyclerion Therapeutics Inc. stockJuly 2025 Sector Moves & Low Risk High Win Rate Stock Picks - Newser
Cyclerion Therapeutics (CYCN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Is Cyclerion Therapeutics Inc. stock attractive for growth ETFsPortfolio Risk Report & Free Long-Term Investment Growth Plans - Newser
Cyclerion Receives Milestone Payment from Akebia - TipRanks
Cyclerion Therapeutics Inc Stock (CYCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.32%
1.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):